RecruitingNCT06994494

Noninvasive Continuous BP Monitoring in Newborns Based on Pulsatile Signal Morphological Features Using NIRS


Sponsor

Massachusetts General Hospital

Enrollment

80 participants

Start Date

Apr 9, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this study is to evaluate if a novel near-infrared spectroscopy (NIRS) device can accurately estimate blood pressure in newborns at risk for unstable blood pressure. The main questions it aims to answer are: * Can NIRS accurately estimate blood pressure when compared to the gold standard, arterial line blood pressure * Can NIRS accurately estimate blood pressure when compared to infants with cuff blood pressure monitoring Researchers will compare NIRS-based estimates to arterial line blood pressure readings and manual cuff measurements to optimize and validate the FlexNIRS device for neonates to accurately estimate blood pressure continuously and noninvasively. Participants will wear a small, noninvasive NIRS sensor on the forehead.


Eligibility

Min Age: 24 WeeksMax Age: 44 Weeks

Inclusion Criteria4

  • Neonates ≥24 \& <44 weeks postmenstrual age
  • Hospitalization in MGH or BWH newborn service units
  • For A-line BP monitoring: Neonates expected to maintain A-line monitoring for at least the next 12 hours
  • For non-A-line monitoring: Neonates at risk for unstable blood pressure (e.g. clinical instability or need for inotropes) and no contraindications to manual cuff BP measurements every 1 to 4 hours

Exclusion Criteria2

  • Contraindication to FlexNIRS device placement on the scalp/head
  • Underlying congenital/genetic anomalies

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Massachusettes General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06994494


Related Trials